The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Differential Roles of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Angiogenesis
Open accessAbstract
Vascular endothelial growth factor (VEGF)-A, a major regulator for angiogenesis, binds and activates two tyrosine kinase receptors, VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1). These receptors regulate physiological as well as pathological angiogenesis. VEGFR2 has strong tyrosine kinase activity, and transduces the major signals for angiogenesis. However, unlike other representative tyrosine kinase receptors which use the Ras pathway, VEGFR2 mostly uses the Phospholipase-Cgamma-Protein kinase-C pathway to activate MAP-kinase and DNA synthesis. VEGFR2 is a direct signal transducer for pathological angiogenesis including cancer and diabetic retinopathy, thus, VEGFR2 itself and the signaling appear to be critical targets for the suppression of these diseases. VEGFR1 plays dual role, a negative role in angiogenesis in the embryo most likely by trapping VEGF-A, and a positive role in adulthood in a tyrosine kinase-dependent manner. VEGFR1 is expressed not only in endothelial cells but also in macrophage-lineage cells, and promotes tumor growth, metastasis, and inflammation. Furthermore, a soluble form of VEGFR1 was found to be present at abnormally high levels in the serum of preeclampsia patients, and induces proteinurea and renal dysfunction. Therefore, VEGFR1 is also an important target in the treatment of human diseases. Recently, the VEGFR2-specific ligand VEGF-E (Orf-VEGF) was extensively characterized. Interestingly, the activation of VEGFR2 via VEGF-E in vivo results in a strong angiogenic response in mice with minor side effects such as inflammation compared with VEGF-A, suggesting VEGF-E to be a novel material for pro-angiogenic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931 · cited 4×
“5 in mesodermal cells of the tail region (Kaipainen et al., 1993; Shalaby et al., 1995).”
BackgroundInfluentialCirculating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Cited by
Molecular regulation of angiogenesis and lymphangiogenesis
Adams, R. H., & Alitalo, K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2183 · Cited by 2,019
Molecular control of endothelial cell behaviour during blood vessel morphogenesis
Herbert, S. P., & Stainier, D. Y. R. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3176 · Cited by 1,042
The role of microenvironment in tumor angiogenesis
Jiang, X., Wang, J., Deng, X., Xiong, F., Zhang, S., Gong, Z., Li, X., Cao, K., Deng, H., He, Y., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01709-5 · Cited by 761
Dynamics of endothelial cell behavior in sprouting angiogenesis
Eilken, H. M., & Adams, R. H. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.08.010 · Cited by 561
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
Role and Therapeutic Potential of VEGF in the Nervous System
Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., & Carmeliet, P. (2009) · Physiological Reviews · doi:10.1152/physrev.00031.2008 · Cited by 448
Regulation of Osteogenesis-Angiogenesis Coupling by HIFs and VEGF
Schipani, E., Maes, C., Carmeliet, G., & Semenza, G. L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090602 · Cited by 406
VEGF: an Essential Mediator of Both Angiogenesis and Endochondral Ossification
Dai, J., & Rabie, A. B. M. (2007) · Journal of Dental Research · doi:10.1177/154405910708601006 · Cited by 404
Karamysheva, A. F. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908070031 · Cited by 386
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
McArthur, K., Feng, B., Wu, Y., Chen, S., & Chakrabarti, S. (2011) · Diabetes · doi:10.2337/db10-1557 · Cited by 329
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Cao, Y. (2009) · Science Signaling · doi:10.1126/scisignal.259re1 · Cited by 289
Phospholipase signalling networks in cancer
Park, J. B., Lee, C. S., Jang, J.-H., Ghim, J., Kim, Y.-J., You, S., Hwang, D., Suh, P.-G., & Ryu, S. H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3379 · Cited by 276
Susceptibility loci for intracranial aneurysm in European and Japanese populations
Bilguvar, K., Yasuno, K., Niemelä, M., Ruigrok, Y. M., von und zu Fraunberg, M., van Duijn, C. M., van den Berg, L. H., Mane, S., Mason, C. E., Choi, M., et al. (2008) · Nature Genetics · doi:10.1038/ng.240 · Cited by 273
Pochon, S., Tardy, I., Bussat, P., Bettinger, T., Brochot, J., von Wronski, M., Passantino, L., & Schneider, M. (2010) · Investigative Radiology · doi:10.1097/rli.0b013e3181c5927c · Cited by 266
A review of anti-VEGF agents for proliferative diabetic retinopathy
Osaadon, P., Fagan, X. J., Lifshitz, T., & Levy, J. (2014) · Eye · doi:10.1038/eye.2014.13 · Cited by 265
Role of microRNAs in diabetes and its cardiovascular complications
Shantikumar, S., Caporali, A., & Emanueli, C. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvr300 · Cited by 263
The molecular mechanisms of hemodialysis vascular access failure
Brahmbhatt, A., Remuzzi, A., Franzoni, M., & Misra, S. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.019 · Cited by 259
Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47
Kaur, S., Martin-Manso, G., Pendrak, M. L., Garfield, S. H., Isenberg, J. S., & Roberts, D. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172304 · Cited by 235
Wong, E., Rosen, L. S., Mulay, M., VanVugt, A., Dinolfo, M., Tomoda, C., Sugawara, M., & Hershman, J. M. (2007) · Thyroid · doi:10.1089/thy.2006.0308 · Cited by 206
Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4905 · Cited by 149
Tam, J., Duda, D. G., Perentes, J. Y., Quadri, R. S., Fukumura, D., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004974 · Cited by 99
“VEGFR1 was previously thought to be a nonsignaling ‘‘decoy’’ receptor, but recent studies have demonstrated its involvement in pathologic angiogenesis [7] and the recruitment of BMDCs [8], including macrophages and endothelial precursor cells [9].”
BackgroundLv, T., Li, Z., Xu, L., Zhang, Y., Chen, H., & Gao, Y. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.06.034 · Cited by 74
Decreased serum angiogenin level in Alzheimer's disease
Kim, Y. N., & Kim, D. H. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.010 · Cited by 55
Metadata
- Authors
- Shibuya, M.
- Venue
- BMB Reports
- Published
- 2006-09-30
- Volume
- 39
- Issue
- 5
- Pages
- 469-478
- ISSN
- 1976-6696 (ISSN-L)
- OpenAlex
- W2004918005
- Cited by
- 623
- References
- 77
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.